catb  stock quote for catabasis pharmaceuticals inc  msn money msn back to msn home money web search sign in change language  content américa latina español argentina español australia english belgië nederlands belgique français brasil português canada english canada français chile español colombia español danmark dansk deutschland deutsch españa español france français india english indonesia bahasa indonesia ireland english italia italiano malaysia english méxico español nederland nederlands new zealand english norge norsk bokmål österreich deutsch perú español philippines english polska polski portugal português schweiz deutsch singapore english south africa english suisse français suomi suomi sverige svenska türkiye türkçe united arab emirates english united kingdom english united states english united states español venezuela español việt nam tiếng việt ελλάδα ελληνικά россия pусский ישראל עברית‏ الإمارات العربية المتحدة العربية‏ المملكة العربية السعودية العربية‏ مصر العربية‏ ไทย ไทย 한국 한국어      語   switch to latino español feedback help adchoices catabasis pharmaceuticals inc nasdaq catb us markets open in hr  min adchoices     after hours     july    pm edt delayed  minutes nasdaq currency in usd save summary financials analysis options ownership company history related open  previous close  volume avg k k days range  wk range  market cap m dividend rate  yield  beta  shares outstanding m pe ratio eps  recent news friedreichs ataxia frda therapeutics pipeline to receive various drug designations from the usfda and ema in the coming years ps market research benzinga  hr ago company overview of catabasis pharmaceuticals inc bloomberg  days ago key executives for catabasis pharmaceuticals inc bloomberg  catabasis pharmaceuticals to report second quarter  financial results and recent corporate developments on thursday august  bioportfoliocom  mins ago catabasis pharmaceuticals inc marketsftcom  days ago catabasis pharmaceuticals inc catb receives an update from brokers desotoedgecom  days ago new report examines the nonalcoholic steatohepatitis pipeline market for therapeutics h  whatech  catabasis pharmaceuticals inc nasdaqcatb receives  consensus target price from brokerages breeze  brokerages anticipate catabasis pharmaceuticals inc nasdaqcatb will post earnings of  per share breeze  cystic fibrosis pipeline drug therapeutics development h  advfncom  catabasis pharmaceuticals catb receives daily media sentiment score of  themarketsdailycom  catabasis pharmaceuticals inc catb ukinvestingcom  catabasis pharmaceuticals nasdaqcatb receiving positive press coverage study shows fumbleboardcom  catabasis pharmaceuticals inc nasdaqcatb present data from part a and part b of movedmd trial benchmarkmonitorcom  catabasis pharmaceuticals to present results from the movedmd® trial of edasalonexent cat at the  ppmd annual connect conference wallstreet online  catabasis pharmaceuticals to present results from the movedmd® trial of edasalonexent cat at the  ppmd annual connect conference tmcnetcom  catabasis pharmaceuticals to present results from the movedmd® trial of edasalonexent cat at the  ppmd annual connect conference bioportfoliocom  catabasis pharmaceuticals to present results from the movedmd® trial of edasalonexent cat at the  ppmd annual connect conference digital journal  adchoices adchoices adchoices markets dow dow ▲    last updated time   pm edt markets nasdaq nasdaq ▲    ftse  ftse  ▼    nyse composite nyse composite ▼    adchoices feedback send feedback provide feedback report a problem we appreciate your input select a category im having problems with top destinations im having issues searching im having problems with featured apps i see an error in the content other how we can improve please give an overall site rating submit close privacy statement help help  support catabasis bringing hope and lifechanging therapies to patients  their families we develop therapies for patients with rare diseases learn more our lead candidate is a potential diseasemodifying therapy that may benefit all boys affected by duchenne muscular dystrophy regardless of their mutation type learn more join us in transforming science into lifechanging therapies learn more our story we are a team of experts from multiple disciplines who have come together driven to bring hope and lifechanging therapies to patients and their families   learn more june   catabasis pharmaceuticals to present results from the movedmd® trial of edasalonexent cat at the  ppmd annual connect conference june   catabasis pharmaceuticals presents new data for cat as a novel potential oral treatment for cystic fibrosis at the th european cystic fibrosis society conference june   catabasis pharmaceuticals to present cat a novel activator of autophagy as a potential treatment for cystic fibrosis at the th european cystic fibrosis society conference patients  families we are honored and proud to be members of the duchenne muscular dystrophy dmd community – one that is built on strength and determination   learn more science  technology each of our product candidates is created with our proprietary smart linker drug discovery platform to address a critical challenge in drug discovery the benefit of modulating multiple biological targets simultaneously to treat diseases successfully   learn more one kendall square bldg e suite b cambridge ma                  infocatabasiscom one kendall square bldg e suite b cambridge ma   infocatabasiscom  copyright   all rights reserved    terms of use    privacy statement join our team contact us investor overview  catabasis pharmaceuticals inc skip to main navigation investor overview overview at catabasis pharmaceuticals our mission is to bring hope and lifechanging therapies to patients and their families our smart safely metabolized and rationally targeted linker drug discovery platform enables us to engineer molecules that simultaneously modulate multiple targets in a disease we are applying our smart linker platform to build an internal pipeline of product candidates for rare diseases and plan to pursue partnerships to develop additional product candidates recent news july   at  am edt summary togglecatabasis pharmaceuticals to report second quarter  financial results and recent corporate developments on thursday august  june   at  am edt summary togglecatabasis pharmaceuticals to present results from the movedmd® trial of edasalonexent cat at the  ppmd annual connect conference june   at  am edt summary togglecatabasis pharmaceuticals presents new data for cat as a novel potential oral treatment for cystic fibrosis at the th european cystic fibrosis society conference i r contact ir contact andrea matthewsphone  email amatthewscatabasiscom upcoming events year  any  items per page  there are currently no events to display the documents contained in or directly accessible from this website include forwardlooking statements within the meaning of the private securities litigation reform act of  including statements containing the words “believes” “expects” “anticipates” “plans” “estimates” and similar expressions there are a number of important factors that could cause catabasis’ actual results to differ materially from those indicated by such forwardlooking statements including factors identified in the company’s most recent reports filed with the sec the company disclaims any intention or obligation to update any forwardlooking statements as a result of developments occurring after the date such statement was first made one kendall square bldg e suite b cambridge ma                  infocatabasiscom  copyright   all rights reserved     terms of use     privacy statement join our team contact us catbnasdaq gm stock quote  catabasis pharmaceuticals inc  bloomberg markets error could not add to watchlist x  watchlist catabasis pharmaceuticals inc catbus nasdaq gm usd   as of  pm edt  open  day range    volume  previous close  wk range     yr return  before its here its on the bloomberg terminal learn more open  day range    volume  previous close  wk range     yr return  ytd return  current pe ratio ttm  earnings per share usd ttm  market cap m usd  shares outstanding m  pricesales ttm  dividend indicated gross yield  sector health care  price change  industry pharmaceuticals biotechnology  life sciences  price change  related videos there are currently no related videos for this ticker please check back later company news press releases  catabasis drops after muscular dystrophy drug fails  investopedia  catabasis muscular dystrophy drug posts early win  investopedia there are currently no news stories for this ticker please check back later  minutes ago catabasis pharmaceuticals to report second quarter  financial results and recent corporate developments on thursday august  cystic fibrosis therapeutics pipeline h  research report available at rnr market research  catabasis pharmaceuticals to present results from the movedmd® trial of edasalonexent cat at the  ppmd annual  catabasis pharmaceuticals presents new data for cat as a novel potential oral treatment for cystic fibrosis at the th  catabasis pharmaceuticals to present cat a novel activator of autophagy as a potential treatment for cystic fibrosis at  amyotrophic lateral sclerosis therapeutic pipeline market  key players orphazyme aps apopharma inc and biohealthonomics  catabasis pharmaceuticals reports first quarter  financial results and reviews business progress  catabasis pharmaceuticals to report first quarter  financial results and recent corporate developments on thursday may   catabasis pharmaceuticals announces favorable results for functional assessments in the movedmd® trial for edasalonexent in  catabasis pharmaceuticals to present at the american academy of neurology th annual meeting there are currently no press releases for this ticker please check back later profile catabasis pharmaceuticals inc operates as a clinicalstage biopharmaceutical company focused on the discovery development and commercialization of therapeutics the companys initial focus is on treatments for rare diseases while also developing other product candidates for the treatment of serious lipid disorders address  kendall squarebuilding e suite bcambridge ma united states phone  website wwwcatabasiscom executives board members jill c milne presidentceocofounder michael jirousek mike chief scientific ofcrcofounder andrew nichols andy chief scientific officer ted hibben chief business officer deirdre a cunnane sr vptreasurergen cnsl show more catabasis pharmaceuticals inc  product pipeline review   infowiseguyreportscom     chat with us           us         uk login register home report categories premium reports access to  premium reports aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports report categories aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports publisher knowledgestore countries browse by country browse by continent browse by group  region conferences upcoming conferences seminars conferences upcoming conferences seminars countries browse by country browse by continent browse by group  region news  blog press release blog news  blogs press release blogs faqs about us about our company our team life at wgr careers contact us there are no items currently in your basket there are no items currently in your basket search home all reports catabasis pharmaceuticals inc  product pipeline review catabasis pharmaceuticals inc  product pipeline review   wgr  october  global  pages global markets direct description table of content sample report enquiry before buy related reports catabasis pharmaceuticals inc  product pipeline review  summaryglobal markets direct’s ‘catabasis pharmaceuticals inc  product pipeline review  ’ provides an overview of the catabasis pharmaceuticals inc’s pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of catabasis pharmaceuticals inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescope the report provides brief overview of catabasis pharmaceuticals inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of catabasis pharmaceuticals inc’s human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones  special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement  latest news and deals relating to the catabasis pharmaceuticals inc’s pipeline productsreasons to buy evaluate catabasis pharmaceuticals inc’s strategic position with total access to detailed information on its product pipeline assess the growth potential of catabasis pharmaceuticals inc in its therapy areas of focus identify new drug targets and therapeutic classes in the catabasis pharmaceuticals inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of catabasis pharmaceuticals inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of catabasis pharmaceuticals inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of catabasis pharmaceuticals inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contentstable of contents list of tables list of figures catabasis pharmaceuticals inc snapshot catabasis pharmaceuticals inc overview key information key facts catabasis pharmaceuticals inc  research and development overview key therapeutic areas catabasis pharmaceuticals inc  pipeline review pipeline products by stage of development pipeline products  monotherapy catabasis pharmaceuticals inc  pipeline products glance catabasis pharmaceuticals inc  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities catabasis pharmaceuticals inc  early stage pipeline products preclinical productscombination treatment modalities catabasis pharmaceuticals inc  drug profiles cat product description mechanism of action rd progress cat series product description mechanism of action rd progress cat product description mechanism of action rd progress cat product description mechanism of action rd progress cat product description mechanism of action rd progress cat product description mechanism of action rd progress cat series product description mechanism of action rd progress cat product description mechanism of action rd progress cat series product description mechanism of action rd progress cat product description mechanism of action rd progress catabasis pharmaceuticals inc  pipeline analysis catabasis pharmaceuticals inc  pipeline products by target catabasis pharmaceuticals inc  pipeline products by route of administration catabasis pharmaceuticals inc  pipeline products by molecule type catabasis pharmaceuticals inc  pipeline products by mechanism of action catabasis pharmaceuticals inc  recent pipeline updates catabasis pharmaceuticals inc  dormant projects catabasis pharmaceuticals inc  locations and subsidiaries head office appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablescatabasis pharmaceuticals inc key information catabasis pharmaceuticals inc key facts catabasis pharmaceuticals inc  pipeline by indication  catabasis pharmaceuticals inc  pipeline by stage of development  catabasis pharmaceuticals inc  monotherapy products in pipeline  catabasis pharmaceuticals inc  phase ii  catabasis pharmaceuticals inc  phase i  catabasis pharmaceuticals inc  preclinical  catabasis pharmaceuticals inc  pipeline by target  catabasis pharmaceuticals inc  pipeline by route of administration  catabasis pharmaceuticals inc  pipeline by molecule type  catabasis pharmaceuticals inc  pipeline products by mechanism of action  catabasis pharmaceuticals inc  recent pipeline updates  catabasis pharmaceuticals inc  dormant developmental projects list of figurescatabasis pharmaceuticals inc  pipeline by top  indication  catabasis pharmaceuticals inc  pipeline by stage of development  catabasis pharmaceuticals inc  monotherapy products in pipeline  catabasis pharmaceuticals inc  pipeline by top  target  catabasis pharmaceuticals inc  pipeline by top  route of administration  catabasis pharmaceuticals inc  pipeline by top  molecule type  catabasis pharmaceuticals inc  pipeline products by top  mechanism of action   request a sample report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro do you have any specific field of interest confirm make an enquiry before buying this report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro your enquiry confirm purchase this market research report usd gbp euro yen inr user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  add to cart buy now   email report   sample report   save page   any questions   download information   check discount   download order form   email report   sample report   save page   any questions   download information   check discount   download order form contact us akash anand domain head business development saleswiseguyreportscom     us     uk rishabh arora domain head business development saleswiseguyreportscom  abu koshy domain head business development saleswiseguyreportscom     related reports × tell a friend about this report your name your email friends name friends email your enquiry send catabasis pharmaceuticals inc nasdaqcatb quotes  news  google financecookies help us deliver our services by using our services you agree to our use of cookieslearn moregot itmy accountsearchmapsyoutubeplaynewsgmaildrivecalendargoogletranslatephotosmoreshoppingwalletfinancedocsbooksbloggercontactshangoutskeepeven more from googlesign inhidden fieldssearch financeadobe flash player is required for interactive charts allowfinancecatabasis pharmaceuticals incnasdaqcatbadd to portfoliocompanysummarynewsrelated companieshistorical pricesfinancialsmarketsnewsportfoliosstock screenergoogle domestic trendsrecent quotes  daysyou have no recent quoteschg   catabasis pharmaceuticals inc  public nasdaqcatb   watch this stock      after hours    jul  pm edt   nasdaq realtime data  disclaimer currency in usd range     week    open  vol  avg  mkt cap m pe      divyield      eps  shares m beta      inst own  news relevance date all news for catabasis pharmaceuticals inc » subscribe advertisement events add catb to my calendars aug   q  catabasis pharmaceuticals inc earnings release estimated  pm edt  may   q  catabasis pharmaceuticals inc earnings call may   q  catabasis pharmaceuticals inc earnings release more events from dailyfinance »     key stats and ratios q mar   net profit margin   operating margin   ebitd margin   return on average assets   return on average equity   employees   cdp score   screen stocks with similar metrics » address  kendall sq bldg e ste bcambridge ma united states  map phone fax website links httpwwwcatabasiscom external links analyst estimates  marketwatch sec filings  edgar online major holders  msn money research reports  reuters settings  technicals  link to this view volume delayed by  minsprices are not from all markets sources include six advertisement related companies show most recent quarter most recent annual add or remove columns save changes cancel sector healthcare  industry bio therapeutic drugs more from factset » description catabasis pharmaceuticals inc is a clinicalstage biopharmaceutical company the company is focused on the discovery development and commercialization of therapeutics based on its safely metabolized and rationally targeted smart a linker drug discovery platform the smart linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease the companys primary focus is on treatments for rare diseases the company is also developing other product candidates for the treatment of lipid disorders the companys cat is a smart linker conjugate of salicylate a nonsteroidal antiinflammatory drug and the omega fatty acid docosahexaenoic acid dha a naturally occurring unsaturated fatty acid with antiinflammatory properties its cat series product candidates inhibit the sterol regulatory element binding protein srebp pathway the companys cat is a smart linker conjugate of monomethyl fumarate and dha more from reuters » officers and directors kenneth m bate cochairman of the board age  bio  compensation   reuters michael jay ross ph d director cochairman of the board of directors age  bio  compensation   reuters jill c milne phd president chief executive officer cofounder director age  bio  compensation   reuters deirdre a cunnane jd senior vice president general counsel treasurer age  bio  compensation   reuters andrew nichols phd chief scientific officer age  bio  compensation   reuters joanne m donovan md phd chief medical officer age  bio  compensation   reuters edward hibben chief business officer age  bio  compensation   reuters burt a adelman md independent director age  bio  compensation   reuters jean m george independent director age  bio  compensation   reuters michael d kishbauch independent director age  bio  compensation   reuters full list on reuters » google finance beta available in hong kong  canada  us  china  ukinformation is provided as is and solely for informational purposes not for trading purposes or advice and may be delayedto see all exchange delays please see disclaimer google  google home  blog  help  report a problem  privacy policy  terms of service catabasis pharmaceuticals inc private company information  bloomberg july    am et biotechnology company overview of catabasis pharmaceuticals inc snapshot people company overview catabasis pharmaceuticals inc a clinicalstage biopharmaceutical company focuses on the discovery development and commercialization of therapeutic products based on safely metabolized and rationally targeted smart linker drug discovery platform in the united states the company offers edasalonexent an investigational oral small molecule which is in phase iii clinical trial for the treatment of duchenne muscular dystrophy dmd it is also involved in developing smart linker conjugates that are in preclinical stage of development including cat for cystic fibrosis cf trafficking and function of cf transmembrane conductance regulator as well as for the clearance of pseudomon catabasis pharmaceuticals inc a clinicalstage biopharmaceutical company focuses on the discovery development and commercialization of therapeutic products based on safely metabolized and rationally targeted smart linker drug discovery platform in the united states the company offers edasalonexent an investigational oral small molecule which is in phase iii clinical trial for the treatment of duchenne muscular dystrophy dmd it is also involved in developing smart linker conjugates that are in preclinical stage of development including cat for cystic fibrosis cf trafficking and function of cf transmembrane conductance regulator as well as for the clearance of pseudomonas aeruginosa and cat for the treatment of severe and rare neurodegenerative diseases such as friedreichs ataxia and amyotrophic lateral sclerosis the company has preclinical joint research collaboration agreement with sarepta therapeutics inc to explore a combination drug treatment approach for dmd catabasis pharmaceuticals inc was founded in  and is based in cambridge massachusetts detailed description building eone kendall squaresuite bcambridge ma united statesfounded in  employees phone  fax  wwwcatabasiscom key executives for catabasis pharmaceuticals inc ms jill c milne phd cofounder ceo president  director age  total annual compensation k dr michael jirousek phd cofounder and member of scientific advisory board age  total annual compensation k dr joanne m donovan md phd chief medical officer  senior vp of clinical development age  total annual compensation k dr andrew j nichols phd chief scientific officer age  total annual compensation k compensation as of fiscal year  catabasis pharmaceuticals inc key developments catabasis pharmaceuticals inc approves election of kenneth bate as class ii director from class iii director jun   catabasis pharmaceuticals inc announced that upon his election as a class ii director of the company at the annual meeting of stockholders held on june   kenneth bate who previously served as a class iii director of the company resigned as class iii director catabasis pharmaceuticals inc reports unaudited consolidated earnings results for the first quarter ended march   may   catabasis pharmaceuticals inc reported unaudited consolidated earnings results for the first quarter ended march   for the quarter loss from operations was  against  for the same period prior year net loss was  against  for the same period prior year net loss per share  basic and diluted was  against  for the same period prior year net cash used in operating activities was  against  for the same period prior year catabasis pharmaceuticals inc to report q  results on may   apr   catabasis pharmaceuticals inc announced that they will report q  results at  pm eastern standard time on may   similar private companies by industry company name region n labs inc united states andme inc united states c tech corporation inc united states v biosciences inc united states bar biologics inc united states recent private companies transactions typedate target no transactions available in the past  months request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact catabasis pharmaceuticals inc please visit wwwcatabasiscom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close catabasis pharmaceuticals to present results from the movedmd® trial of edasalonexent cat at the  ppmd annual connect conference  catabasis pharmaceuticals inc skip to main navigation press release view printerfriendly version  back catabasis pharmaceuticals to present results from the movedmd® trial of edasalonexent cat at the  ppmd annual connect conference cambridge massbusiness wirejun   catabasis pharmaceuticals inc nasdaqcatb a clinicalstage biopharmaceutical company today announced that it will present data from part a and part b of the movedmd trial of edasalonexent cat in an oral presentation at the upcoming  parent project muscular dystrophy ppmd annual connect conference to be held june  – july   in chicago il at the chicago marriott downtown joanne donovan md phd chief medical officer of catabasis will deliver a presentation titled “movedmd phase  trial of edasalonexent an nfkb inhibitor in  to year old patients with duchenne muscular dystrophy” on friday june   from pm – pm ct about edasalonexent catedasalonexent cat is an investigational oral small molecule that is being developed as a potential diseasemodifying therapy for all patients affected by dmd regardless of their underlying mutation edasalonexent inhibits nfkb a protein that is activated in dmd and drives inflammation and fibrosis muscle degeneration and suppresses muscle regeneration we are currently conducting the movedmd trial a threepart clinical trial investigating the safety and efficacy of edasalonexent in boys ages  –  affected with dmd any confirmed mutation the third part of the trial an openlabel extension with edasalonexent is ongoing the fda has granted orphan drug fast track and rare pediatric disease designations and the european commission has granted orphan medicinal product designation to edasalonexent for the treatment of dmd for a summary of clinical results reported todate please visit wwwcatabasiscom about catabasisat catabasis pharmaceuticals our mission is to bring hope and lifechanging therapies to patients and their families our smart safely metabolized and rationally targeted linker drug discovery platform enables us to engineer molecules that simultaneously modulate multiple targets in a disease we are applying our smart linker platform to build an internal pipeline of product candidates for rare diseases and plan to pursue partnerships to develop additional product candidates for more information on the companys drug discovery platform and pipeline of drug candidates please visit wwwcatabasiscom view source version on businesswirecom httpwwwbusinesswirecomnewshomeen source catabasis pharmaceuticals inc investor and media contactcatabasis pharmaceuticals incandrea matthews amatthewscatabasiscom one kendall square bldg e suite b cambridge ma                  infocatabasiscom  copyright   all rights reserved     terms of use     privacy statement join our team contact us catabasis pharmaceuticals inc  product pipeline review   trends statistics segment and forecasts market size share analysis  market research store     gmt office hours  uscan toll free  us office no home categories become publisher news about us contact us select category consumer goods food  beverage heavy industry life sciences marketing  market research public sector service industries technology  media semiconductor chemical and materials metallurgical market research search home  life sciences  pharmaceuticals catabasis pharmaceuticals inc  product pipeline review   published jun  format pdf  global markets direct  number of pages   code mrs   report details table of content inquiry for buying request sample catabasis pharmaceuticals inc  product pipeline review   summary global markets direct’s ‘catabasis pharmaceuticals inc  product pipeline review  ’ provides an overview of the catabasis pharmaceuticals inc’s pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of catabasis pharmaceuticals inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects global markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope  the report provides brief overview of catabasis pharmaceuticals inc including business description key information and facts and its locations and subsidiaries  the report reviews current pipeline of catabasis pharmaceuticals inc’s human therapeutic division and enlists all their major and minor projects  the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones  special feature on outlicensed and partnered product portfolio  the report summarizes all the dormant and discontinued pipeline projects  latest company statement  latest news and deals relating to the catabasis pharmaceuticals inc’s pipeline products reasons to buy  evaluate catabasis pharmaceuticals inc’s strategic position with total access to detailed information on its product pipeline  assess the growth potential of catabasis pharmaceuticals inc in its therapy areas of focus  identify new drug targets and therapeutic classes in the catabasis pharmaceuticals inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas  exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps  develop strategic initiatives by understanding the focus areas of catabasis pharmaceuticals inc and exploit collaboration and partnership opportunities  identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage  plan mergers and acquisitions effectively by identifying the most promising pipeline of catabasis pharmaceuticals inc  develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope  explore the dormant and discontinued projects of catabasis pharmaceuticals inc and identify potential opportunities in those areas  avoid intellectual property rights related issues table of contents table of contents  list of tables  list of figures  catabasis pharmaceuticals inc snapshot  catabasis pharmaceuticals inc overview  key information  key facts  catabasis pharmaceuticals inc  research and development overview  key therapeutic areas  catabasis pharmaceuticals inc  pipeline review  pipeline products by stage of development  pipeline products  monotherapy  catabasis pharmaceuticals inc  pipeline products glance  catabasis pharmaceuticals inc  clinical stage pipeline products  phase ii productscombination treatment modalities  phase i productscombination treatment modalities  catabasis pharmaceuticals inc  early stage pipeline products  preclinical productscombination treatment modalities  catabasis pharmaceuticals inc  drug profiles  cat  product description  mechanism of action  rd progress  cat  product description  mechanism of action  rd progress  cat series  product description  mechanism of action  rd progress  cat  product description  mechanism of action  rd progress  cat  product description  mechanism of action  rd progress  cat  product description  mechanism of action  rd progress  cat  product description  mechanism of action  rd progress  cat series  product description  mechanism of action  rd progress  cat series  product description  mechanism of action  rd progress  cat  product description  mechanism of action  rd progress  catabasis pharmaceuticals inc  pipeline analysis  catabasis pharmaceuticals inc  pipeline products by target  catabasis pharmaceuticals inc  pipeline products by route of administration  catabasis pharmaceuticals inc  pipeline products by molecule type  catabasis pharmaceuticals inc  pipeline products by mechanism of action  catabasis pharmaceuticals inc  recent pipeline updates  catabasis pharmaceuticals inc  dormant projects  catabasis pharmaceuticals inc  locations and subsidiaries  head office  appendix  methodology  coverage  secondary research  primary research  expert panel validation  contact us  disclaimer  list of tables catabasis pharmaceuticals inc key information  catabasis pharmaceuticals inc key facts  catabasis pharmaceuticals inc  pipeline by indication   catabasis pharmaceuticals inc  pipeline by stage of development   catabasis pharmaceuticals inc  monotherapy products in pipeline   catabasis pharmaceuticals inc  phase ii   catabasis pharmaceuticals inc  phase i   catabasis pharmaceuticals inc  preclinical   catabasis pharmaceuticals inc  pipeline by target   catabasis pharmaceuticals inc  pipeline by route of administration   catabasis pharmaceuticals inc  pipeline by molecule type   catabasis pharmaceuticals inc  pipeline products by mechanism of action   catabasis pharmaceuticals inc  recent pipeline updates   catabasis pharmaceuticals inc  dormant developmental projects  list of figures catabasis pharmaceuticals inc  pipeline by top  indication   catabasis pharmaceuticals inc  pipeline by stage of development   catabasis pharmaceuticals inc  monotherapy products in pipeline   catabasis pharmaceuticals inc  pipeline by top  target   catabasis pharmaceuticals inc  pipeline by top  route of administration   catabasis pharmaceuticals inc  pipeline by top  molecule type   catabasis pharmaceuticals inc  pipeline products by top  mechanism of action   inquiry for buying please fill your details below to inquire about this report  indicates required fields name email phone name of company titledesignation country name select country andorra united arab emirates afghanistan antigua and barbuda anguilla albania armenia angola antarctica argentina american samoa austria australia aruba åland islands azerbaijan bosnia and herzegovina barbados bangladesh belgium burkina faso bulgaria bahrain burundi benin saint barthélemy bermuda brunei darussalam bolivia plurinational state of bonaire sint eustatius and saba brazil bahamas bhutan bouvet island botswana belarus belize canada cocos keeling islands congo the democratic republic of the central african republic congo switzerland côte divoire cook islands chile cameroon china colombia costa rica cuba cape verde curaçao christmas island cyprus czech republic germany djibouti denmark dominica dominican republic algeria ecuador estonia egypt western sahara eritrea spain ethiopia finland fiji falkland islands malvinas micronesia federated states of faroe islands france gabon united kingdom grenada georgia french guiana guernsey ghana gibraltar greenland gambia guinea guadeloupe equatorial guinea greece south georgia and the south sandwich islands guatemala guam guineabissau guyana hong kong heard island and mcdonald islands honduras croatia haiti hungary indonesia ireland israel isle of man india british indian ocean territory iraq iran islamic republic of iceland italy jersey jamaica jordan japan kenya kyrgyzstan cambodia kiribati comoros saint kitts and nevis korea democratic peoples republic of korea republic of kuwait cayman islands kazakhstan lao peoples democratic republic lebanon saint lucia liechtenstein sri lanka liberia lesotho lithuania luxembourg latvia libya morocco monaco moldova republic of montenegro saint martin french part madagascar marshall islands macedonia the former yugoslav republic of mali myanmar mongolia macao northern mariana islands martinique mauritania montserrat malta mauritius maldives malawi mexico malaysia mozambique namibia new caledonia niger norfolk island nigeria nicaragua netherlands norway nepal nauru niue new zealand oman panama peru french polynesia papua new guinea philippines pakistan poland saint pierre and miquelon pitcairn puerto rico palestinian state of portugal palau paraguay qatar réunion romania serbia russian federation rwanda saudi arabia solomon islands seychelles sudan sweden singapore saint helena ascension and tristan da cunha slovenia svalbard and jan mayen slovakia sierra leone san marino senegal somalia suriname south sudan sao tome and principe el salvador sint maarten dutch part syrian arab republic swaziland turks and caicos islands chad french southern territories togo thailand tajikistan tokelau timorleste turkmenistan tunisia tonga turkey trinidad and tobago tuvalu taiwan province of china tanzania united republic of ukraine uganda united states minor outlying islands united states uruguay uzbekistan holy see vatican city state saint vincent and the grenadines venezuela bolivarian republic of virgin islands british virgin islands us viet nam vanuatu wallis and futuna samoa yemen mayotte south africa zambia zimbabwe how can we help you refresh captcha submit request sample please fill your details below to receive sample report  indicates required fields name email phone name of company titledesignation country name select country andorra united arab emirates afghanistan antigua and barbuda anguilla albania armenia angola antarctica argentina american samoa austria australia aruba åland islands azerbaijan bosnia and herzegovina barbados bangladesh belgium burkina faso bulgaria bahrain burundi benin saint barthélemy bermuda brunei darussalam bolivia plurinational state of bonaire sint eustatius and saba brazil bahamas bhutan bouvet island botswana belarus belize canada cocos keeling islands congo the democratic republic of the central african republic congo switzerland côte divoire cook islands chile cameroon china colombia costa rica cuba cape verde curaçao christmas island cyprus czech republic germany djibouti denmark dominica dominican republic algeria ecuador estonia egypt western sahara eritrea spain ethiopia finland fiji falkland islands malvinas micronesia federated states of faroe islands france gabon united kingdom grenada georgia french guiana guernsey ghana gibraltar greenland gambia guinea guadeloupe equatorial guinea greece south georgia and the south sandwich islands guatemala guam guineabissau guyana hong kong heard island and mcdonald islands honduras croatia haiti hungary indonesia ireland israel isle of man india british indian ocean territory iraq iran islamic republic of iceland italy jersey jamaica jordan japan kenya kyrgyzstan cambodia kiribati comoros saint kitts and nevis korea democratic peoples republic of korea republic of kuwait cayman islands kazakhstan lao peoples democratic republic lebanon saint lucia liechtenstein sri lanka liberia lesotho lithuania luxembourg latvia libya morocco monaco moldova republic of montenegro saint martin french part madagascar marshall islands macedonia the former yugoslav republic of mali myanmar mongolia macao northern mariana islands martinique mauritania montserrat malta mauritius maldives malawi mexico malaysia mozambique namibia new caledonia niger norfolk island nigeria nicaragua netherlands norway nepal nauru niue new zealand oman panama peru french polynesia papua new guinea philippines pakistan poland saint pierre and miquelon pitcairn puerto rico palestinian state of portugal palau paraguay qatar réunion romania serbia russian federation rwanda saudi arabia solomon islands seychelles sudan sweden singapore saint helena ascension and tristan da cunha slovenia svalbard and jan mayen slovakia sierra leone san marino senegal somalia suriname south sudan sao tome and principe el salvador sint maarten dutch part syrian arab republic swaziland turks and caicos islands chad french southern territories togo thailand tajikistan tokelau timorleste turkmenistan tunisia tonga turkey trinidad and tobago tuvalu taiwan province of china tanzania united republic of ukraine uganda united states minor outlying islands united states uruguay uzbekistan holy see vatican city state saint vincent and the grenadines venezuela bolivarian republic of virgin islands british virgin islands us viet nam vanuatu wallis and futuna samoa yemen mayotte south africa zambia zimbabwe how can we help you refresh captcha submit related reports opioidinduced constipation oic  pipeline review h  jul  global markets direct  pages    code  mrs   opioidinduced constipation oic  pipeline review h  summary global markets directs latest pharmaceutical and healthcare disease pipeline guide opioidinduced constipation oic  pipeline review h  provides an overview of the opioidinduced constipation oic toxicology pipeline landscape opioids are effective pain relievers but often have the side effect of constipation these medicines affect the gastrointestinal tract in a variety of ways opioids increase the amo read more chemotherapy induced neutropenia  pipeline review h  jul  global markets direct  pages    code  mrs   chemotherapy induced neutropenia  pipeline review h  summary global markets directs latest pharmaceutical and healthcare disease pipeline guide chemotherapy induced neutropenia  pipeline review h  provides an overview of the chemotherapy induced neutropenia toxicology pipeline landscape chemotherapyinduced neutropenia is a very common side effect of cancer treatment symptoms include severe fatigue weakness anxiety lack of energy shortness of breath headaches pa read more chemotherapy induced nausea and vomiting  pipeline review h  jul  global markets direct  pages    code  mrs   chemotherapy induced nausea and vomiting  pipeline review h  summary global markets directs latest pharmaceutical and healthcare disease pipeline guide chemotherapy induced nausea and vomiting  pipeline review h  provides an overview of the chemotherapy induced nausea and vomiting toxicology pipeline landscape chemotherapy induced nausea and vomiting or cinv is nausea and vomiting that results specifically from treatment with chemotherapy drugs symptoms include a rapi read more px purinoceptor  pz receptor or prx  pipeline review h  jul  global markets direct  pages    code  mrs   px purinoceptor  pz receptor or prx  pipeline review h  summary according to the recently published report px purinoceptor   pipeline review h  px purinoceptor  pz receptor or prx pipeline target constitutes close to  molecules out of which approximately  molecules are developed by companies px purinoceptor  pz receptor or prx  px purinoceptor  is a protein encoded by the prx gene it acts as receptor for atp that acts as a ligandgated i read more smoothened homolog protein gx or smo  pipeline review h  jul  global markets direct  pages    code  mrs   smoothened homolog protein gx or smo  pipeline review h  summary smoothened homolog protein gx or smo  smoothened homolog smo is a g proteincoupled receptor that probably associates with the patched protein ptch to transduce the hedgehogs proteins signal binding of sonic hedgehog shh to its receptor is thought to prevent normal inhibition by patched of smoothened smo it is required for the accumulation of kif and gli in the cilia smoothened homolog protein gx read more metabotropic glutamate receptor  gprcd or mglur or grm  pipeline review h  jul  global markets direct  pages    code  mrs   metabotropic glutamate receptor  gprcd or mglur or grm  pipeline review h  summary metabotropic glutamate receptor  gprcd or mglur or grm pipeline target constitutes close to  molecules out of which approximately  molecules are developed by companies and remaining by the universitiesinstitutes the latest report metabotropic glutamate receptor   pipeline review h  outlays comprehensive information on the metabotropic glutamate receptor  gprcd or mglur o read more g protein coupled bile acid receptor  g protein coupled receptor gpcr or membrane type receptor for bile acids or hbg or gpr or gpbar  pipeline review h  jul  global markets direct  pages    code  mrs   g protein coupled bile acid receptor  g protein coupled receptor gpcr or membrane type receptor for bile acids or hbg or gpr or gpbar  pipeline review h  summary according to the recently published report g protein coupled bile acid receptor   pipeline review h  g protein coupled bile acid receptor  g protein coupled receptor gpcr or membrane type receptor for bile acids or hbg or gpr or gpbar pipeline target constitutes close to  molecules out of read more alpha c adrenergic receptor alpha  adrenergic receptor subtype c or alpha c adrenoreceptor or adrac  pipeline review h  jul  global markets direct  pages    code  mrs   alpha c adrenergic receptor alpha  adrenergic receptor subtype c or alpha c adrenoreceptor or adrac  pipeline review h  summary alpha c adrenergic receptor alpha  adrenergic receptor subtype c or alpha c adrenoreceptor or adrac  alphac adrenergic receptor or adrac is an alpha adrenergic receptor it mediates the catecholamineinduced inhibition of adenylate cyclase through the action of g proteins this receptor plays a critical role in regulating neurotransmitt read more tumor necrosis factor receptor superfamily member  glucocorticoid induced tumor necrosis factor receptor or activation inducible tnfr family receptor or glucocorticoid induced tnfr related protein or cd or tnfrsf  pipeline review h  jul  global markets direct  pages    code  mrs   tumor necrosis factor receptor superfamily member  glucocorticoid induced tumor necrosis factor receptor or activation inducible tnfr family receptor or glucocorticoid induced tnfr related protein or cd or tnfrsf  pipeline review h  summary tumor necrosis factor receptor superfamily member  glucocorticoid induced tumor necrosis factor receptor or activation inducible tnfr family receptor or glucocorticoid induced tnfr related protein or cd or tnfrsf pipeline targe read more ephrin type b receptor  hepatoma transmembrane kinase or tyrosine protein kinase tyro or ephb or ec   pipeline review h  jul  global markets direct  pages    code  mrs   ephrin type b receptor  hepatoma transmembrane kinase or tyrosine protein kinase tyro or ephb or ec   pipeline review h  summary according to the recently published report ephrin type b receptor   pipeline review h  ephrin type b receptor  hepatoma transmembrane kinase or tyrosine protein kinase tyro or ephb or ec  pipeline target constitutes close to  molecules out of which approximately  molecules are developed by companies and remaining read more payment mode single user  usd multi user  usd corporate user  usd latest report  global nonslip epoxy glass flake paint market research report  global parking sensors market research report  global nitrogen oxide sensor market research report  global nuclear density gauge market research report  global automotive interior materials market research report view more latest news global chitosan market set for rapid growth to reach usd  billion by  zion market research has published a new report titled chitosan market for water treatment biomed development of ecommerce to reshape global mobile hotspot router market mobile hotspot is a popular feature on smart phones that provide wireless internet access on many global carotenoids market is expected to reach around usd  billion in  zion market research has published a new report titled carotenoids market by type astaxanthin be soaring demand from food  beverages industry to act as prime driving for ascorbic acid market reports zion market research ascorbic acid is extensively available in nature mostly rich in leafy vegetables and fresh fruits global energy management system ems market is set for a rapid growth and is expected to reach usd  million by  zion market research has published a new report titled energy management system market ems by so view more single user  usd view pricing find help how to order disclaimer faqs return policy sitemap our company about us terms and conditions privacy policy we accept the following payment methods     market research store  market research reports catb stock quote  catabasis pharmaceuticals inc common stock price  nasdaqcom hot topics etfs  smart portfolio  currencies  online broker center search home  quotes  catb catabasis pharmaceuticals inc common stock quote  summary data catb      unch unch get catb alerts delayed  data as of jul      find a broker to begin trading catb now exchangenasdaq industry health care community rating view    catb premarket catb     edit symbol list symbol lookup real time nls trade reporting flashquotes infoquotes summary quote charts interactive charts premarket charts after hours charts revenue  eps summary company financials  view competitors  short interest company news press releases company news press releases sentiment analyst stock research stock report sec filings  holdingsinsider summary  institutional holdings  insider form  equity options premarket quotes after hours quotes company research  stockconsultant stock comparison  guru analysis annual report historical quotes call transcripts dividend history lynch analysis graham analysis validea momentum analysis fool analysis dreman analysis zweig analysis fisher analysis oshaughnessy analysis etf detail etf profile comparison charts symbol list views flashquotes infoquotes stock details summary quote realtime quote after hours quote premarket quote historical quote option chain charts basic chart interactive chart company news company headlines press releases market stream stock analysis analyst research guru analysis stock report competitors stock consultant stock comparison fundamentals call transcripts annual report income statement revenueeps sec filings short interest dividend history holdings ownership summary institutional holdings insiderssec form  closex edit symbol list enter up to  symbols separated by commas or spaces in the text box below these symbols will be available during your session for use on applicable pages go now clear list dont know the stock symbol use the symbol lookup tool alphabetize the sort order of my symbols closex   symbol lookup closex investing just got easier… sign up now to become a nasdaqcom member and begin receiving instant notifications when key events occur that affect the stocks you follow access now  save stocks news pricecharts tradehistory annual report earningsreport date dynamic quotes turn off best bidask best bid is the highest price currently being offered for a block of stock best ask is the lowest price currently being asked for a block of stock na  na  year target  todays high low todays high the highest sales price the stock has achieved during the regular trading hours the intraday high todays low the lowest sales price the stock has fallen to during the regular trading hours the intraday low      share volume share volume is the number of shares of the stock traded on the listing exchange during current trading hours it does not include after hours volume   day avg daily volume this is the average share volume for the past  trading days for nasdaq stocks and  trading days for nonnasdaq stocks this field allows you to compare todays trading to the average daily volume  previous close previous close is the previous trading days last reported trade price during official trading hours    week highlow  week high is the highest sales price the stock has achieved during the regular trading hours during the most recent  week period  week low is the lowest sales price the stock has fallen to during the regular trading hours during the most recent  week period      market cap “market capitalization” is a measure of the estimated value of the common equity securities of the company or their equivalent it does not include securities convertible into the common equity securities “market capitalization” is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities as applicable nasdaq does not use this value to determine compliance with the listing requirements   pe ratio pe ratio is a statistic calculated by dividing the price of a stock by the reported actual earnings per share of the issuing firm not the same as the projected pe ratio it is also called the multiple ne forward pey a widely used stock evaluation measure for a security the priceearnings ratio is given by dividing the last sale price by the average eps earnings per share estimate for the specified fiscal time period the forward pe refers to the value for the next full year ne earnings per share eps the eps listed on our infoquote and summary quote page is mos rolling eps represents the portion of a companys profit allocated to each outstanding share of common stock net income reported or estimated for a period of time is divided by the total number of shares outstanding tso during that period see growth rate measures for eps our vendors methodology for the eps on the infoquote and summary quote pages follows the eps used by the majority of the analysts following the stock in many cases this is ebitda eps   annualized dividend na ex dividend date the data is based on historical exdividend data  doesn’t include upcoming values visit the dividend history page to see the upcoming dividend information na dividend payment date na current yield indicated yield represents annual dividends divided by current stock price the data is based on historical exdividend data  doesn’t include upcoming values visit the dividend history page to see the upcoming dividend information   beta beta is a volatility measurement of a stock mutual fund or etf versus a comparable benchmark like the sp  stock index a stock fund or etf with a higher beta than the sp  will rise or fall to a greater degree in contrast a stock fund or etf with a low beta will rise or fall less  nasdaq official open price nasdaq official opening price this process identifies the nasdaqspecific opening prices for nasdaqlisted issues   date of open price date of open price this field refers to the date the nasdaq official open price was disseminated for a given stock it is possible that the date will not be from the current trading day this indicates that the stock didnt trade on nasdaq during the current trading day the nasdaq official open price is updated only when the stock is traded on nasdaq jul   nasdaq official close price nasdaq official closing price nocp is a process for identifying the nasdaq marketspecific closing price for nasdaqlisted issues   date of close price this field refers to the date the nocp was disseminated for a given stock it is possible that the date will not be from the prior day this indicates that the stock didnt trade on nasdaq on the prior day the nocp is updated only when the stock is traded on nasdaq jul   community sentiment intraday chart d m m m more charting company description as filed with the sec we are a clinicalstage biopharmaceutical company focused on the discovery development and commercialization of novel therapeutics based on our proprietary safely metabolized and rationally targeted or smart linker drug discovery platform our smart linker drug discovery platform enables us to engineer product candidates that can simultaneously modulate multiple targets in a disease our proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach we have applied our smart linker drug discovery platform to build an internal pipeline of product candidates for rare diseases our primary focus and plan to pursue partnerships to develop additional product candidates our lead product candidate is edasalonexent formerly known as cat an oral small molecule   more    risk grade where does catb fit in the risk graph news for catb buzzus stocks on the moveyandex delta air lines target teva   am  reuters sarepta appoints exallergan executive as ceo and president   am  zackscom catabasis pharmaceuticals catb investor presentation  slideshow   am  seeking alpha jj jnj plans to seek approval for  new drugs by    am  zackscom orexigen orex obesity drug contrave registers slow growth   am  zackscom  subscribe more catb news  commentary read catb press releases consensus recommendation analyst info annual eps est  quarterly eps est  peg ratio  mean recommendation  data is provided by zacks investment research view all view summary closex edit favorites enter up to  symbols separated by commas or spaces in the text box below these symbols will be available during your session for use on applicable pages update clear list closex customize your nasdaqcom experience background color selector select the background color of your choice  black  slate gray  light gray  gray blue quote search select a default target page for your quote search  realtime  after hours  premarket  news  flash quote  summary quote  interactive charts  default setting please note that once you make your selection it will apply to all future visits to nasdaqcom if at any time you are interested in reverting to our default settings please select default setting above if you have any questions or encounter any issues in changing your default settings please email isfeedbacknasdaqcom closex please confirm your selection you have selected to change your default setting for the quote search this will now be your default target page unless you change your configuration again or you delete your cookies are you sure you want to change your settings yes no closex please disable your ad blocker or update your settings to ensure that javascript and cookies are enabled so that we can continue to provide you with the firstrate market news and data youve come to expect from us closex catabasis bringing hope and lifechanging therapies to patients  their families we develop therapies for patients with rare diseases learn more our lead candidate is a potential diseasemodifying therapy that may benefit all boys affected by duchenne muscular dystrophy regardless of their mutation type learn more join us in transforming science into lifechanging therapies learn more our story we are a team of experts from multiple disciplines who have come together driven to bring hope and lifechanging therapies to patients and their families   learn more june   catabasis pharmaceuticals to present results from the movedmd® trial of edasalonexent cat at the  ppmd annual connect conference june   catabasis pharmaceuticals presents new data for cat as a novel potential oral treatment for cystic fibrosis at the th european cystic fibrosis society conference june   catabasis pharmaceuticals to present cat a novel activator of autophagy as a potential treatment for cystic fibrosis at the th european cystic fibrosis society conference patients  families we are honored and proud to be members of the duchenne muscular dystrophy dmd community – one that is built on strength and determination   learn more science  technology each of our product candidates is created with our proprietary smart linker drug discovery platform to address a critical challenge in drug discovery the benefit of modulating multiple biological targets simultaneously to treat diseases successfully   learn more one kendall square bldg e suite b cambridge ma                  infocatabasiscom one kendall square bldg e suite b cambridge ma   infocatabasiscom  copyright   all rights reserved    terms of use    privacy statement join our team contact us bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one